Background
==========

Overactive bladder disease (OAB) is defined by the Standardization Subcommittee of the International Continence Society (ICS) as urinary urgency, with or without urinary incontinence, usually with frequency and nocturia, with no proven infection or other obvious pathology \[[@B1]\]. As part of the National Overactive Bladder Evaluation (NOBLE) program: 16.5% of the USA population (16% of men and 16.9% of women) over 18 years of age had symptoms consistent with OAB \[[@B2]\]. This translates into approximately 34 million symptomatic people in the USA alone. Of the 16.5% of the adult population with symptoms consistent with OAB, 37.2% were characterized as having OAB with urinary urge incontinence (UUI) \[[@B2]\]. OAB significantly impacts heath related quality of life \[[@B3]\] and is associated with comorbidities such as increased risk of falls and fractures, increased urinary tract and skin infections, sleep disturbances, depression, and decreased sexual health \[[@B4],[@B5]\]. The economic impact of OAB is considerable given its estimated attributable cost of \$12.02 billion in the USA for the year 2000 \[[@B6]\].

Depending on severity and etiology, initial treatment of OAB is characterized by behavioral modification (timed voiding, bladder training, pelvic floor exercises, etc) and antimuscarinic drugs. Behavioral interventions for treating OAB such as bladder training are often the first line therapy for mild symptoms of urge, frequency, and/or incontinence. Bladder training involves patient education, scheduled voiding, and positive reinforcement. Other behavioral interventions include pelvic floor exercises (PFE) and biofeedback. PFEs are thought to inhibit spontaneous bladder contractions and also increase bladder outlet resistance to result in reduced leakage and increased voiding intervals. Biofeedback is a way of notifying the patient when certain physiologic events are occurring (e.g. unstable bladder contraction or proper PFE contraction).

In a Cochrane review on bladder training, treatment outcomes consisted of patient\'s global observations (perception of a cure or improvement in their incontinence), quantification of symptoms (adverse events, number of incontinence episodes, number of micturitions in day and night), and quality of life (Incontinence Impact Questionnaire and SF-36) \[[@B7]\]. Outcomes in PFEs and biofeedback include the quantification of symptom domains, and urodynamic outcomes \[[@B8]\].

Most urinary incontinent patients initiate treatment with antimuscarinic therapy. Six antimuscarinic drugs are currently marketed worldwide for the treatment of OAB: oxybutynin, tolterodine, propiverine, trospium, darifenacin, and solifenacin \[[@B9]\]. Each product has demonstrated efficacy in treating OAB symptoms but includes such common adverse events as dry mouth, constipation, headache, and blurred vision. In a review of antimuscarinic drugs versus placebo, Nabi and colleagues found that there was a lack of consistency in the types of outcomes reported by trialists \[[@B10]\]. Heterogeneity in urinary incontinence and other clinical characteristics in various OAB trial patient populations may partly describe such differences. We attempted to reduce clinical characteristic heterogeneity by focusing on treatment success definitions in populations that have failed antimuscarinic therapy.

If patients fail oral drug (antimuscarinic) therapy, more invasive interventions are available. Approved implantable neurostimulator devices have been used with some success, sacral neuromodulation (SNM), but are costly \[[@B11]\]. Surgical options such as augmentation cystoplasty (AC), and neobladder construction, or urinary diversion are available, but are limited to those that have failed the previous mentioned techniques due to elevated risk profile and complexity of the surgeries. Although still in phase II and phase III studies, botulinum toxin type A (BoNTA) is emerging as a potential treatment option for idiopathic and neurogenic OAB with urinary urge incontinence, respectively \[[@B12]\].

Clinicians, payers, and other health care decision makers all have interest in determining whether or not a patient management strategy is successful. In part due to patient heterogeneity, interventions that are indicated for the management of OAB with UUI lack standardization in the measurement of treatment response or treatment success. A consistent and validated treatment success metric would allow for more efficient use of healthcare resources, facilitating the clinician and patient to more transparently weigh the risk-benefit profile of treatment alternatives. A standardized success outcome would also permit more consistent value for money assessments across and beyond OAB interventions.

The objectives of this research are to review common treatment success outcomes used in both idiopathic and neurogenic OAB with UUI, focusing on the different antimuscarinic refractory intervention classes and to recommend a measure of treatment success for clinical research and health economic applications.

Methods
=======

Review Methodology
------------------

We performed a review of studies that published treatment success outcomes for OAB patients with UUI refractory to antimuscarinic therapy. A computerized search of PubMed and the grey literature including the Google search engine was conducted for studies published between 1998 and 2008. Studies were also obtained from references of published reviews and accepted studies. Studies published prior to 1998 were not included in part due to the lack of appropriate outcome development. Search terms used for retrieval of botulinum toxin studies were \"botulinum A toxin overactive bladder,\" sacral neuromodulation were \"sacral neuromodulation overactive bladder,\" and surgical treatment studies were \"augmentation overactive bladder OR clam augmentation.\" Abstracts were excluded from this literature review if they were not published in English, published as a review, used botulinum toxin type B as treatment, was a dose determining or safety study, included a patient population that did not have urinary urge incontinence, was conducted in animals or in pediatrics, or conducted as a case series. In addition, we required included studies to report a measure of treatment success in terms of the proportion of the study population. Data extracted from the studies included; study design, patient characteristics, intervention, follow up time, definition of success, and proportion of participants that succeeded. In our analysis we summarized by definition of treatment success, the proportion of patients that succeeded the intervention of study.

Treatment Success Association
-----------------------------

We selected the best candidate for a treatment success definition based in part on its emphasis and use as reported in the literature. We associated this candidate definition using patient level data from a clinical study of 59 patients with neurogenic urinary incontinence \[[@B13]\]. We investigated the relationship between the identified/recommended treatment success measure and both generic and disease-specific health-related quality of life (HRQoL) outcomes. We used the Incontinence Quality of Life Questionnaire (I-QOL) \[[@B14]\] as an estimate of the disease-specific HRQoL and preference scores from the SF-6D as an estimate of generic HRQoL. We followed the methods outlined by Brazier et al to convert existing SF-36 data into preference scores (range 0-1) \[[@B15]\]. The I-QOL is an incontinence-specific measure that has shown high levels of validity and reliability in stress incontinence, overactive bladder and neurogenic detrusor overactivity \[[@B14],[@B16]\]. The I-QOL consists of 22 items that fall within three domains: avoidance and limiting behavior; psychosocial impacts; and social embarrassment. For each item, subjects assign a value on a 5-point Likert scale from 1 (extremely) to 5 (not at all). The total scale score for all 22-items is transformed to a 0 (extreme incontinence problems) to 100 (no incontinence problems) range.

We performed two-sample t-tests assuming equal variances to estimate the mean difference in the I-QOL and SF-6D change scores for treatment success versus treatment failure patients. The minimal important difference (MID) observed for the I-QOL instrument was a change in the total score of at least 6.3 for patients with stress urinary incontinence \[[@B17]\]. We used the MID as a benchmark to determine if the average difference observed in the I-QOL was clinically meaningful. Although the Schurch et al. study intervention was BoNTA compared to placebo, we did not adjust for treatment assignment or any other baseline characteristics in the validation of the treatment success outcome.

Results
=======

Botulinum Toxin Type A (BoNTA)
------------------------------

There is an emerging body of evidence in support of the efficacy and safety of using BoNTA in OAB \[[@B12]\]. A review by Duthie and colleagues of randomized or quasi-randomized controlled trials of BoNTA found similar outcomes reported as in the antimuscarinic therapy reviews \[[@B18]\]. Changes in incontinence rates were the most frequently reported efficacy outcome followed by urinary frequency, health-related quality of life, and urodynamic measures of cystometric capacity and detrusor pressure. Schurch summarized BoNTA published studies including those with non-randomized designs for the neurogenic and idiopathic OAB populations \[[@B19]\]. One result from Schurch\'s review was a summary of the study specific success rates stratified by the neurogenic and idiopathic populations. Success in this instance was broadly based on the proportion of patients who met a threshold of reduced incontinence episodes.

The search of BoNTA studies yielded 165 abstracts for review (Figure [1](#F1){ref-type="fig"}). A total of 11 articles met inclusion criteria and an additional 17 articles were retrieved from published reviews or references of accepted articles.

![**Study search yield by intervention**.](1471-2490-9-18-1){#F1}

Sacral Neuromodulation (SNM)
----------------------------

Brazzelli and colleagues provided a review of SNM that includes a discussion of outcomes used to demonstrate the efficacy and safety as well as the success of the device \[[@B20]\]. A more unified definition of success has been reported within the SNM literature. Namely, the term \"cured\" was equated to at least a 90% reduction in incontinence symptoms and \"improved\" meant greater than a 50% reduction in incontinence symptoms. Together, a \"cured\" or \"improved\" patient was thought to have succeeded on SNM. Other outcome measures such as pad usage, incontinence severity, voiding frequency, urodynamic parameters, and health-related quality of life were reported to secondarily demonstrate efficacy, but not with the same consistency as the cured or improved rates. Safety outcomes mainly focused on adverse events such as reoperations, replacement or relocation of the device, permanent explants, generator or electrode/lead failures, pain, infection, wound problems, and adverse bowl function.

The search of SNM studies produced 86 abstracts for review (Figure [1](#F1){ref-type="fig"}). From these, 4 articles were included and 7 studies came from references of review articles.

Augmentation Cystoplasty Surgery (AC)
-------------------------------------

Augmentation cystoplasty (AC) is a surgery where a segment of the bowel is removed and patched to the bisected bladder. This method increases bladder capacity and decreases bladder pressure caused by unstable contractions. Risks of this surgery include kidney or bladder infections, new recurrent UTIs, metabolic derangements, mucus production, and in rare cases tumors within the bladder. Khastgir et al. described outcomes measured for augmentation cystoplasty \[[@B21]\]. The emphasized outcomes were clinical outcomes (maximum detrusor pressure and bladder volume capacity) and the quantification of patient symptoms (incontinence episodes and number of pads). Other outcomes included a questionnaire that measured symptoms and disease specific quality of life, and the evaluation of complications from the surgery. An alternative to augmentation cystoplasty is detrusor myectomy where an excision of the detrusor muscle from the top of the bladder results in a bulge in the epithelium and in turn increases storage capacity of the bladder. Although this procedure is less risky, it is also thought to be less effective. Similar outcomes emphasizing the clinical and symptoms domains have been measured for detrusor myectomy \[[@B22]\].

The search of AC studies produced 51 abstracts for review (Figure [1](#F1){ref-type="fig"}). A total of 4 studies were included from the search, 3 studies from references of review articles, and 2 studies from references of other accepted studies.

Summary overall interventions
-----------------------------

Across BoNTA, SNM, and AC for OAB with UUI, 48 studies met the entry criteria for the review of treatment success definitions (58.3% BoNTA, 22.9% SNM, and 18.8% AC). Due to a small percentage of studies reporting more than one definition of treatment success, the total number of treatment success definitions was 52. Achieving complete continence was reported as a definition of treatment success 23 times (44%) (Table [1](#T1){ref-type="table"}). Achieving at least a ≥ 50% reduction in incontinence episodes (or other symptoms) was reported as a definition of treatment success 16 times (31%) (Table [2](#T2){ref-type="table"}). Subjective patient satisfaction measures were reported as a definition of treatment success 13 times (25%) (Table [3](#T3){ref-type="table"}). Achieving at least a ≥ 50% reduction in incontinence episodes (or other symptoms) was the most common definition for the idiopathic population (42%) whereas complete continence was the most common definition for the neurogenic population (59%). We now present supporting evidence for the ≥ 50% reduction in incontinence episodes as a measure of treatment success.

###### 

Complete Continence: Treatment Success Definition by Intervention

  Study                                                    Study Design   Sample Size   Study Population   Comparator                      Success Evaluated (months)   Success %
  -------------------------------------------------------- -------------- ------------- ------------------ ------------------------------- ---------------------------- -----------
  **Botulinum toxin type A**                                                                                                                                            
  Kennelly, Top Spinal Cord Inj Rehabil, 2003 \[[@B26]\]   Open Label     10            NOAB               None                            6                            80
  Reitz, Eur Urol, 2004 \[[@B27]\]                         Open Label     200           NOAB               None                            4                            73
  Giannantoni, J Urol, 2004 \[[@B28]\]                     RCT            25            NOAB               Intravesically Resiniferation   18                           73
  Giannantoni, Minerva Urol Nephrol, 2004 \[[@B29]\]       RCT            12            NOAB               Intravesically Resiniferation   12                           75.0
  Klaphajone, Arch Phys Med Rehabil, 2005 \[[@B30]\]       Open Label     10            NOAB               None                            1.5                          70
  Schurch, J Urol, 2005 \[[@B13]\]                         RCT            38            NOAB               Placebo                         6                            63
  Kessler, Neurourol Urodynam, 2005\* \[[@B31]\]           Open Label     11, 11        NOAB, IOAB         None                            3, 3                         72, 91
  Popat, J Urol, 2005\* \[[@B32]\]                         Open Label     31, 44        NOAB, IOAB         None                            4, 4                         55.2, 57
  Werner, Am J Obstet Gynecol, 2005 \[[@B33]\]             Open Label     26            IOAB               None                            9                            65
  Kuo, J Urol, 2006\* \[[@B34]\]                           Single Blind   35, 40        NOAB, IOAB         None                            3, 3                         94, 73
  Giannantoni, J Urol, 2006 \[[@B35]\]                     Open Label     23            NOAB               None                            3                            78
  Karsenty, Urol, 2006 \[[@B36]\]                          Open Label     17            NOAB               None                            5                            100
  Sahai, J Urol, 2007 \[[@B37]\]                           RCT            16            IOAB               Placebo                         3                            50
  Mascarenhas, Neurourol. Urodynam, 2008 \[[@B38]\]        Open label     21            NOAB               None                            2                            42.8
                                                                                                                                                                        
  **Sacral neuromodulation**                                                                                                                                            
  Bosch, J Urol, 2000 \[[@B39]\]                           Open Label     6             NOAB               None                            47                           80
  Chartier-Kastler, J Urol, 2000 \[[@B40]\]                Open Label     9             NOAB               None                            43.6                         67
  Weil, Eur Urol, 2000 \[[@B41]\]                          RCT            21            IOAB               Current Management              6                            56
  Spinelli, J Urol, 2001 \[[@B42]\]                        Open Label     196           NOAB               None                            18                           71
                                                                                                                                                                        
  **Augmentation cystoplasty**                                                                                                                                          
  Chartier-Kaslter, Spinal Cord, 2000 \[[@B43]\]           Open Label     17            NOAB               None                            75.6                         70.5
  Ivil, Int Urol Nephrol, 2002 \[[@B44]\]                  Open Label     17            IOAB               None                            11                           83
  Khastgir, Eur Urol, 2003 \[[@B21]\]                      Open Label     32            NOAB               None                            72                           100
  Quek, J Urol, 2003 \[[@B45]\]                            Open Label     26            NOAB               None                            96                           69
  Stoffel, Neurourol Urodynam, 2006 \[[@B46]\]             Open Label     12            NOAB               None                            20                           88

\* Denotes a study with both neurogenic OAB (NOAB) and idiopathic OAB (IOAB) populations.

Note: Studies may be listed in more than one category of treatment success if multiple definitions of treatment success were reported.

###### 

≥ 50% Improvement in Incontinence Episodes or Other Symptoms: Treatment Success Definition by Intervention

  Study                                               Study Design   Sample Size   Study Population   Comparator           Success Evaluated (months)   Success %
  --------------------------------------------------- -------------- ------------- ------------------ -------------------- ---------------------------- -----------
  **Botulinum toxin type A**                                                                                                                            
  Flynn, J Urol, 2004 \[[@B47]\]                      Open Label     7             IOAB               None                 3                            100
  Kuo, Urology, 2004\* \[[@B48]\]                     Open Label     12, 8         NOAB, IOAB         None                 3, 3                         66.6, 75
  Kuo, Urology, 2005 \[[@B49]\]                       Open Label     20            IOAB               None                 3                            85
  Kalsi, Eur Urol, 2006\* \[[@B50]\]                  Open Label     63, 38        NOAB, IOAB         None                 4, 4                         86, 79
  Kalsi, Ann Neurol, 2007 \[[@B51]\]                  Open Label     43            NOAB               None                 4                            80
  Mascarenhas, Neurourol. Urodynam, 2008 \[[@B38]\]   Open label     21            NOAB               None                 2                            52.4
                                                                                                                                                        
  **Sacral neuromodulation**                                                                                                                            
  Schmidt, J Urol, 1999 \[[@B52]\]                    RCT            34            IOAB               Current Management   6                            75
  Bosch, J Urol, 2000 \[[@B39]\]                      Open Label     40            IOAB               None                 47                           60
  Amundsen, Am J Obstet Gynecol, 2002 \[[@B53]\]      Open Label     12            IOAB               None                 7                            100
  Bosch, J Urol, 2000 \[[@B39]\]                      Open Label     6             NOAB               None                 47                           100
  Hassouna, J Urol, 2000 \[[@B54]\]                   RCT            25            IOAB               Current Management   6                            56
  Scheepens, Eur Urol, 2003 \[[@B55]\]                Open Label     34            IOAB               None                 11                           53
  Van Voskuilen, BJU Int, 2007 \[[@B56]\]             Open Label     31            IOAB               None                 15.5                         90
  Groenendijk, BJU Int, 2008 \[[@B57]\]               Open Label     67            IOAB               None                 6                            61
  Wallace, Am J Obstet Gynecol, 2007 \[[@B58]\]       Open Label     33            NOAB               None                 12.5                         84.8
                                                                                                                                                        
  **Augmentation cystoplasty**                                                                                                                          
  Blaivas, J Urol, 2005 \[[@B59]\]                    Open Label     76            NOAB               None                 106.8                        97

\* Denotes a study with both neurogenic OAB (NOAB) and idiopathic OAB (IOAB) populations.

Note: Studies may be listed in more than one category of treatment success if multiple definitions of treatment success were reported.

###### 

Subjective Improvement: Treatment Success Definition by Intervention

  Study                                            Study Design   Sample Size   Study Population   Comparator   Success Evaluated (months)   Success %
  ------------------------------------------------ -------------- ------------- ------------------ ------------ ---------------------------- -----------
  **Botulinum toxin type A**                                                                                                                 
  Loch, Eur Urol Supp, 2003\* \[[@B60]\]           Open Label     30, 30        NOAB, IOAB         None         8, 8                         67, 67
  Rapp, Urology, 2004 \[[@B61]\]                   Open Label     35            IOAB               None         6                            60
  Grosse, Eur Urol, 2005 \[[@B62]\]                Open Label     66            NOAB               None         10                           86.3
  Rajkumar, BJU Int, 2005 \[[@B63]\]               Open Label     15            IOAB               None         1.5                          93
  Schulte-Baukloh, Eur Urol, 2005 \[[@B64]\]       Open Label     44            IOAB               None         3                            86
  Schmid, J Urol, 2006 \[[@B65]\]                  Open Label     100           IOAB               None         3                            88
  Schulte-Baukloh, Neur Urodyn, 2006 \[[@B66]\]    Open Label     16            NOAB               None         6                            100
  Kuo, J Urol, 2007 \[[@B67]\]                     Open Label     45            IOAB               None         3                            80
                                                                                                                                             
  **Augmentation cystoplasty**                                                                                                               
  Edlund, Scand J Urol Nephrol, 2001 \[[@B68]\]    Open Label     25            IOAB               None         60                           78
  Barrington, Int Urogynecol J, 2006 \[[@B69]\]    Open Label     12            IOAB               None         12                           83
  Chartier-Kaslter, Spinal Cord, 2000 \[[@B43]\]   Open Label     17            NOAB               None         75.6                         88.5
  Quek, J Urol, 2003 \[[@B45]\]                    Open Label     26            NOAB               None         96                           96
  Nomura, Spinal Cord, 2002 \[[@B70]\]             Open Label     11            NOAB               None         66                           100

\* Denotes a study with both neurogenic OAB (NOAB) and idiopathic OAB (IOAB) populations.

Note: Studies may be listed in more than one category of treatment success if multiple definitions of treatment success were reported.

Treatment Success Association: ≥ 50% reduction in incontinence episodes
-----------------------------------------------------------------------

Of the 51 patients reporting incontinence scores at both baseline and at six month visits across all treatment groups in the Schurch et al trial, 25 (49%) achieved the ≥ 50% reduction in incontinence episodes definition of response. Patients with ≥ 50% reduction in incontinence episodes on average had 8.8 higher I-QOL scores (95% CI: -4.7, 22.3) and 0.07 higher SF-6D preference scores (95% CI: 0.02, 0.12).

Discussion
==========

Deriving a definition of treatment success in any disease area poses many challenges, but we argue that the benefits outweigh the harms in undergoing such an exercise in UUI OAB. Possible limitations to a definition of treatment success in UUI OAB include: patient clinical heterogeneity (e.g. UUI OAB patients have varying levels of incontinence), patient preference heterogeneity (e.g. some patients having the same study outcomes may opt to continue treatment whereas others may opt for alternative interventions), and duration of treatment effect (e.g. if incontinence or other symptoms are included in the measure of success, then how often and over what time period should they be measured?). At the population level, a uniform treatment response outcome provides for the comparison across various UUI OAB interventions, gives researchers a clear and achievable target for purposes of trial design, and allows payers to attain better value for money on UUI OAB interventions for their insured population.

Payne and Kelleher recently evaluated three possible treatment response definitions that were informed from the ICS definition of OAB: (i) a reduction by half or more in all baseline symptoms (episodes of urgency, incontinence, nocturia, and voiding frequency per 24 h); (ii) a reduction by half or more in urgency and at least one other symptom; or (iii) resolution of urgency episodes and at least one other symptom \[[@B23]\]. All three treatment response definitions were correlated with significant changes in the King\'s Health Questionnaire. The authors argued that clinical trials and the evidence base in OAB focus on single endpoints such as incontinence episodes or reduction in incontinence, but correctly point out that the ICS definition of OAB mainly targets urgency and secondarily lists the other symptoms of incontinence, nocturia, and increased voiding frequency. One of the main pitfalls in using any of these three proposed treatment response definitions is that there is yet to be a consensus on how to measure urgency in a reliable and valid way \[[@B24]\]. Further, if one is tasked to gather the current and existing evidence across OAB interventions on treatment response, then retrospectively constructing a composite definition of success is nearly impossible.

Taking into account the currently available evidence, the most likely candidates for a definition of OAB with UUI treatment success are measures that focus on reductions in incontinence episodes. The achievement of full continence has been a common metric in BoNTA studies. But in the case of a dichotomous outcome of success (yes/no), full continence likely excludes many patients that are clinically benefiting from treatment. The question then becomes, what is an appropriate threshold in terms of incontinence reduction that resonates as a clinically meaningful improvement yet does not disregard too many patients that are benefiting? We sought out a definition of success that limits misclassification/residual confounding by setting a threshold that most appropriately includes those receiving meaningful clinical benefit while excluding those that experience a measurable benefit that is not clinically relevant.

We recommend that the appropriate threshold for defining OAB with UUI treatment success should be ≥ 50% reduction in incontinence episodes from baseline. We stress that the use of this definition may be sensitive to the baseline incontinence rate and therefore, both the baseline incontinence rate and the change in the rate should be communicated in research findings. In part, the recommendation definition is based on what is currently available and reported in the literature. The ≥ 50% reduction in incontinence episodes treatment response definition has been used across all reviewed intervention classes and is associated with generic and disease specific HRQoL measures. The average difference in the disease specific HRQoL instrument, I-QOL, change scores was higher than the minimal important difference (MID) reported for stress urinary incontinence of 6.3 \[[@B17]\]. Although stress urinary incontinence is not the study population, it is the only known population wherein a MID for the I-QOL has been reported. Additionally, Yalcin et al reported that stress urinary incontinence patients appear to recognize important clinical value at incontinence reductions of approximately 50% \[[@B25]\]. If the MID for OAB with UUI was found to be similar to that in stress urinary incontinence, then the findings from the Schurch et al trial suggest that the recommended treatment success definition is associated with a meaningful improvement in a disease specific HRQoL instrument.

There are several limitations to the study. The primary aim of this research was to review the evidence on treatment success definitions reported for OAB with UUI refractory to oral antimuscarinics. We focused on three primary intervention classes in order to make our literature search tractable. By doing so, we did not summarize treatment success definitions for more rare interventions in this population such as percutaneous tibial nerve stimulation given the limited quantity of published evidence on such interventions. We did not include behavior modification interventions or antimuscarinics because of the anticipated large amount of patient characteristic heterogeneity in this broad population. Increased heterogeneity in UUI symptoms of a population could limit the generalizability of a uniform treatment success definition. The association of the recommended treatment success definition with disease specific and generic HRQoL measures was performed in a BoNTA compared to placebo trial of neurogenic incontinent patients. This same association may not hold for open label studies or those with SNM or AC interventions. Although the recommended treatment success definition of ≥ 50% reduction in incontinence episodes from baseline was the most common observed definition in the idiopathic OAB with UUI population, it should be further validated against other OAB outcomes.

Conclusion
==========

We echo arguments put forth by Payne and Kelleher on the need for a standardized treatment success definition. Moving forward, a success definition like those proposed by Payne and Kelleher that includes many components of the underlying symptoms of OAB (namely urgency) makes clinical sense, but is currently not practical based on difficulties in measuring urgency. Based on the current evidence, we have proposed a definition of success for OAB with UUI that is currently gaining momentum in the literature and is supported by associations with clinically meaningful outcomes. The adoption of the ≥ 50% reduction in incontinence episodes as the treatment response definition for UUI OAB will provide for consistent and valuable outcomes research for both clinical and health economic applications.
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